CLOs on the Move

Auxilium

www.auxilium.com

 
Auxilium is a fully integrated specialty biopharmaceutical company focused on developing and marketing products to predominantly specialist audiences. Auxilium means “assistance” in Latin, and that’s a fitting description for all of our biopharmaceutical development and commercialization efforts. Although we are living in an era of rapid advances in medical technology, many of society’s medical concerns remain unaddressed. Auxilium works to address some of these unmet needs. By doing so, we work in important areas of the pharmaceutical industry that require forward thinking and novel solutions that promote better health and living. Through advancement and expansion, Auxilium is dedicated to providing innovative solutions for ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

Greater Cincinnati Behavioral Health Services

Cincinnati Comprehensive Mental Health Agency helping people through many services and a staff of more than 500 highly skilled professionals.

OnKure Therapeutics

OnKure, Inc. is a biopharmaceutical company focused on the discovery and development of targeted small molecule drugs to improve the outcomes of patients afflicted with cancer. OnKure`s drug candidates aim to treat patients by targeting malignant cells directly, by working in combination with other small molecule therapies and by priming the tumor microenvironment such that checkpoint inhibition is optimized.

Cetylite Industries Inc

Cetylite Industries Inc is a Pennsauken, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

4 dry skin natural products

4 dry skin natural products is a Nashville, KY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Diamedica

DiaMedica Inc., a development stage biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of diabetes and related diseases. The company`s lead clinical stage compound is DM199, a recombinant human protein known as rhKLK1, which is under phase I/II clinical trials for the treatment of Type 1 and Type 2 diabetes and associated complications. It is also developing DM204, a monoclonal antibody that is in preclinical development for the treatment of Type 2 diabetes; and DMDx, a chronic kidney disease assay to detect levels of the tissue kallikrein-1 protein in urine and to predict the rate of kidney disease progression. The company was formerly known as Diabex Inc. and changed its name to DiaMedica Inc. in February 2001. DiaMedica Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.